Our original hypothesis was that deletion of either CR3 or CR4 would potentiate disease development by virtue of impaired parasite clearance thus leading to a more severe course of ECM compared with wild-type mice. To our surprise, there was no difference in survival or clinical disease between the complement receptor mutants and wild-type mice. An alternative outcome may have been reduced disease severity because of altered leucocyte trafficking in the absence of either receptor, mostly due to loss of interaction with ICAM-1 (30–32), which is expressed at high levels on endothelial

surfaces in the CNS during CM and ECM (22,33). Thus, loss of CR3 and CR4 expression on T cells and macrophages could reasonably be expected to reduce adherence and subsequent vascular occlusion, selleck products both characteristic features of CM. We cannot rule out the possibility of compensatory changes in receptor expression during XAV-939 price ECM in either receptor-deficient mouse; however, we have not observed such changes in other CNS inflammatory disease models using these mice (D.C. Bullard and S.R. Barnum, unpublished data). The finding that LFA-1−/− mice are significantly resistant

to the development of ECM, while CR3−/− and CR4−/− mice are not, indicates that, of the β2-integrin family members, LFA-1 plays the most critical role in ECM. Regardless of the potential roles for CR3 and CR4 in ECM pathophysiology, the data we present here support a developing story indicating that, of the complement pathways and components, the complement terminal pathway and the membrane attack complex (MAC) are most important in ECM development. Previous studies have shown that deletion of C5 results in marked increase in resistance to ECM and that inhibition

of C9 (and therefore the MAC) is protective in ECM (25,34). More recently, we have shown that inhibition of the classical or alternative complement pathways does not alter the course of ECM. Furthermore, deletion of C3 does not prevent C5 cleavage indicating that the canonical C5 convertases selleckchem are not wholly responsible for C5 cleavage during ECM (25). The data we present here indicate that the opsonophagocytic functions of the complement system at the level of C3-derived fragments is also not critical for the development and progression of ECM. Thus, in the murine CM model system, biological functions of the complement system derived from components and activation pathways prior to C5 cleavage play a minor role in ECM pathophysiology. Taken together, these data indicate that targeting C5 or components of the MAC may offer a new therapeutic avenue for CM. This work was supported by NIH grants T32 AI07051 and NS077811 (to TNR), AI08382 (to SRB). The authors gratefully acknowledge the continuing support of Drs. Julian Rayner and Oliver Billker.